Companion Diagnostics Market by Technology Type (Immunohistochemistry, Polymerase Chain Reaction [PCR], Next Generation Sequencing [NGS], In Situ Hybridization, and Others), and Indication (Oncology, Neurology, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026

Companion Diagnostics Market Outlook- 2026

The global companion diagnostics market generated USD 1,678 million in 2018, and is projected to reach USD 6,452  million by 2026, growing at a CAGR of 18.3% from 2019 to 2026.

 

A companion diagnostic is an in vitro medical device that provides information which is essential for the safe and effective use of a corresponding drug or biological product. This diagnostic test helps a health care professional to determine whether a particular therapeutic product is beneficial to patients and can outweigh any potential serious side effects or risks. 

The companion diagnostics market is expected to experience significant growth during the forecast period owing to surge in R&D of targeted therapies, rise in demand for personalized medicine with increase in awareness in emerging economies, discovery of new biomarkers for various conditions, and higher number of unmet needs for the treatment of cancer are majorly driving the growth of the global companion diagnostics market.

 

COMPANION DIAGNOSTICS MARKET SEGMENTATION  

The global companion diagnostics market is segmented based on technology type, indication, and region. Based on technology type, the market is classified as immunohistochemistry, polymerase chain reaction (PCR), next generation sequencing (NGS), in situ hybridization, and others. Based on indication, the market is classified as oncology, neurology, and others. The oncology segment is further segmented into lung cancer, colorectal cancer, breast cancer, blood cancer, and others. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa and rest of LAMEA).  

Segment review

Based on technology, the PCR segment dominates the global market, and is anticipated to continue this trend during the forecast period. Some key factors that drive the market growth are cost effectiveness, high sensitivity, and specificity and can be used for simple automated platforms. Furthermore, the sequencing of unknown etiologies of many diseases can be determined by the PCR, which is another key driver of this segment. However, the next generation sequencing segment is estimated to experience rapid growth during the forecast period owing to its key advantages such as higher sensitivity to detect low-frequency variants, lower turnaround time for high sample volumes, ability to sequence hundreds to thousands of genes or gene regions simultaneously etc. are majorly driving the market growth.Oncomine Dx Target Test, FoundationOne CDx, FoundationFocus CDxBRCA Assay and others use next generation sequencing for detection.

 

Based on indication, the global companion diagnostics market is segmented into oncology, neurology, and others. At present, the oncology segment is the major revenue generating segment and is estimated to experience significant growth during the forecast period. 

Some key factors such as higher prevalence of cancer, rise in number of R&D activities for cancer, higher number of unmet needs for treatment of cancer, rise in number of FDA approved companion diagnostics, and increasing awareness among the patients about personalized medicine are majorly driving the growth of the oncology segment.

Research in cancer has identified significant differences in gene sequence and expression patterns that can be the basis for targeted therapy. Furthermore, many biomarkers have been identified for different cancers, for which companion diagnostics have been developed. Companion diagnostics are widely used in different forms of cancer such as lung cancer, colorectal cancer, breast cancer, blood cancer, which are the major cause of the death. 

The companion diagnostics market share is higher for breast cancer as there are many companion diagnostics developed for detection of breast cancer mutations; with a large number of target populations.

 

Snapshot of Asia-Pacific companion diagnostics market

Asia-Pacific presents lucrative opportunities for the key players operating in the companion diagnostics market, owing to high population base, growth in awareness about companion diagnostics, development in healthcare infrastructure, and increase in demand for advanced therapies. However, higher costs incurred in R&D to develop companion diagnostics can hamper the companion diagnostics market growth in Asia-Pacific.

 

The key players profiled in this report include Abbott Laboratories Molecular, Inc., Agilent (Dako Denmark A/S), ARUP Laboratories, Inc., BioMerieux SA, Danaher Corporation (Leica Microsystems), Foundation Medicine, Inc., Myriad Genetics, Inc., Qiagen N.V., Roche (Ventana Medical Systems, Inc.), and Thermo Fisher Scientific (Life Technologies Corporation). 

Key Benefits for Companion Diagnostics Market:

• The study provides an in-depth analysis of the companion diagnostics market size along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive companion diagnostics market analysis of all the regions is provided to determine the prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Companion Diagnostics Key Market Segments:

By Technology Type

• Immunohistochemistry
• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• In Situ Hybridization
• Others

By Indication 

• Oncology
• Neurology
• Others 

By Region

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• France
• UK
• Rest of Europe
• Asia-Pacific
• Japan
• China 
• Australia
• Rest of Asia-Pacific
• LAMEA
• Brazil
• South Africa
• Rest of LAMEA

 

CHAPTER 1:    INTRODUCTION

1.1.    Report description

1.2.    Key benefits for stakeholders

1.3.    Key market segments

1.3.1.    List of key players profiled in the report

1.4.    Research methodology

1.4.1.    Secondary research

1.4.2.    Primary research

1.4.3.    Analyst tools and models

 

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    Key findings of the study

2.2.    Key findings

2.2.1.    Top investment pockets

2.2.2.    Top impacting factors

2.3.    CXO perspective

 

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope

3.2.    Key forces shaping companion diagnostics industry/market

3.2.1.    Moderate power of suppliers

3.2.2.    High threat of new entrants

3.2.3.    Low threat of substitution

3.2.4.    Moderate competitive rivalry

3.2.5.    Moderate power of buyers

3.3.    Parent/ peer market overview

3.5.    Market evolution/industry roadmap

3.6.    Government regulations for companion diagnostics

3.7.    Market dynamics

3.7.1.    Drivers

3.7.1.1.    Increased popularity of personalized medicine

3.7.1.2.    Increase in cases of adverse drug reactions (ADRs)

3.7.1.3.    Surge in healthcare expenditure worldwide

3.7.1.4.    Technological advancements in diagnostic techniques

3.7.2.    Restraints

3.7.2.1.    Unfavorable reimbursement policies in some countries

3.7.3.    Opportunities

3.7.3.1.    Growth opportunities in emerging markets

3.7.3.2.    Increase in incidence of cancer across the globe

3.7.4.    Impact analysis

 

CHAPTER 4:    COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Immunohistochemistry

4.2.1.    Market size and forecast, by region

4.2.2.    Market analysis, by country

4.3.    Polymerase chain reaction (PCR)

4.3.1.    Market size and forecast, by region

4.3.2.    Market analysis, by country

4.4.    Next generation sequencing (NGS)

4.4.1.    Market size and forecast, by region

4.4.2.    Market analysis, by country

4.5.    In situ hybridization

4.5.1.    Market size and forecast, by region

4.5.2.    Market analysis, by country

4.6.    Others

4.6.1.    Market size and forecast, by region

4.6.2.    Market analysis, by country

 

CHAPTER 5:    COMPANION DIAGNOSTICS MARKET, BY INDICATION

5.1.    Overview

5.1.1.    Market size and forecast

5.2.    Oncology

5.2.1.    Key market trends and opportunities

5.2.2.    Market size and forecast, by type

5.2.2.1.    Lung cancer

5.2.2.1.1.    Market size and forecast

5.2.2.2.    Colorectal cancer

5.2.2.2.1.    Market size and forecast

5.2.2.3.    Breast cancer

5.2.2.3.1.    Market size and forecast

5.2.2.4.    Blood cancer

5.2.2.4.1.    Market size and forecast

5.2.2.5.    Others

5.2.2.5.1.    Market size and forecast

5.2.3.    Market size and forecast

5.2.4.    Market analysis, by country

5.3.    Neurology

5.3.1.    Market size and forecast

5.3.2.    Market analysis, by country

5.4.    Others

5.4.1.    Market size and forecast

5.4.2.    Market analysis, by country

 

CHAPTER 6:    COMPANION DIAGNOSTICS MARKET, BY REGION

6.1.    Overview

6.1.1.    Market size and forecast

6.2.    North America

6.2.1.    Key market trends, growth factors, and opportunities

6.2.2.    Market size and forecast, by country

6.2.2.1.    U.S.

6.2.2.1.1.    U.S. companion diagnostics market, by technology

6.2.2.1.2.    U.S. companion diagnostics market, by indication

6.2.2.2.    Canada

6.2.2.2.1.    Canada companion diagnostics market, by technology

6.2.2.2.2.    Canada companion diagnostics market, by indication

6.2.2.3.    Mexico

6.2.2.3.1.    Mexico companion diagnostics market, by technology

6.2.2.3.2.    Mexico companion diagnostics market, by indication

6.2.3.    North America market size and forecast, by technology

6.2.4.    North America Market size and forecast, by indication

6.3.    Europe

6.3.1.    Key market trends, growth factors, and opportunities

6.3.2.    Market size and forecast, by country

6.3.2.1.    Germany

6.3.2.1.1.    Germany companion diagnostics market, by technology

6.3.2.1.2.    Germany companion diagnostics market, by indication

6.3.2.2.    France

6.3.2.2.1.    France companion diagnostics market, by technology

6.3.2.2.2.    France companion diagnostics market, by indication

6.3.2.3.    UK

6.3.2.3.1.    UK companion diagnostics market, by technology

6.3.2.3.2.    UK companion diagnostics market, by indication

6.3.2.4.    Rest of Europe

6.3.2.4.1.    Rest of Europe companion diagnostics market, by technology

6.3.2.4.2.    Rest of Europe companion diagnostics market, by indication

6.3.3.    Europe market size and forecast, by technology

6.3.4.    Europe Market size and forecast, by indication

6.4.    Asia-Pacific

6.4.1.    Key market trends, growth factors, and opportunities

6.4.2.    Market size and forecast, by country

6.4.2.1.    Japan

6.4.2.1.1.    Japan companion diagnostics market, by technology

6.4.2.1.2.    Japan companion diagnostics market, by indication

6.4.2.2.    China

6.4.2.2.1.    China companion diagnostics market, by technology

6.4.2.2.2.    China companion diagnostics market, by indication

6.4.2.3.    Australia

6.4.2.3.1.    Australia companion diagnostics market, by technology

6.4.2.3.2.    Australia companion diagnostics market, by indication

6.4.2.4.    Rest of Asia-Pacific

6.4.2.4.1.    Rest of Asia-Pacific companion diagnostics market, by technology

6.4.2.4.2.    Rest of Asia-Pacific companion diagnostics market, by indication

6.4.3.    Asia-Pacific market size and forecast, by technology

6.4.4.    Asia-Pacific Market size and forecast, by indication

6.5.    LAMEA

6.5.1.    Key market trends, growth factors, and opportunities

6.5.2.    Market size and forecast, by country

6.5.2.1.    Brazil

6.5.2.1.1.    Brazil companion diagnostics market, by technology

6.5.2.1.2.    Brazil companion diagnostics market, by indication

6.5.2.2.    South Africa

6.5.2.2.1.    South Africa companion diagnostics market, by technology

6.5.2.2.2.    South Africa companion diagnostics market, by indication

6.5.2.3.    Rest of LAMEA

6.5.2.3.1.    Rest of LAMEA companion diagnostics market, by technology

6.5.2.3.2.    Rest of LAMEA companion diagnostics market, by indication

6.5.3.    LAMEA market size and forecast, by technology

6.5.4.    LAMEA Market size and forecast, by indication

 

CHAPTER 7:    COMPETITIVE LANDSCAPE

7.1.    Introduction

7.1.1.    Market player positioning, 2018

7.2.    Top winning strategies

7.3.    Competitive dashboard

7.4.    Competitive heatmap

 

CHAPTER 8:    COMPANY PROFILES

8.1.    Abbott Laboratories Molecular, Inc.

8.1.1.    Company overview

8.1.2.    Company snapshot

8.1.3.    Operating business segments

8.1.4.    Product portfolio

8.1.5.    Business performance

8.1.6.    Key strategic moves and developments

8.2.    Agilent (Dako Denmark A/S)

8.2.1.    Company overview

8.2.2.    Company snapshot

8.2.3.    Operating business segments

8.2.4.    Product portfolio

8.2.5.    Business performance

8.2.6.    Key strategic moves and developments

8.3.    ARUP Laboratories, Inc.

8.3.1.    Company overview

8.3.2.    Company snapshot

8.3.3.    Operating business segments

8.3.4.    Service portfolio

8.4.    BioMerieux

8.4.1.    Company overview

8.4.2.    Company snapshot

8.4.3.    Operating business segments

8.4.4.    Product portfolio

8.4.5.    Business performance

8.5.    Danaher Corporation (Leica Microsystems)

8.5.1.    Company overview

8.5.2.    Company snapshot

8.5.3.    Operating business segments

8.5.4.    Product portfolio

8.5.5.    Business performance

8.6.    Foundation Medicine, Inc.

8.6.1.    Company overview

8.6.2.    Company snapshot

8.6.3.    Operating business segments

8.6.4.    Service portfolio

8.6.5.    Key strategic moves and developments

8.7.    Myriad Genetics, Inc.

8.7.1.    Company overview

8.7.2.    Company snapshot

8.7.3.    Operating business segments

8.7.4.    Product portfolio

8.7.5.    Business performance

8.7.6.    Key strategic moves and developments

8.8.    Roche (Ventana Medical Systems, Inc)

8.8.1.    Company overview

8.8.2.    Company snapshot

8.8.3.    Operating business segments

8.8.4.    Product portfolio

8.8.5.    Business performance

8.8.6.    Key strategic moves and developments

8.9.    Thermo Fisher Scientific (Life Technologies Corporation)

8.9.1.    Company overview

8.9.2.    Company snapshot

8.9.3.    Operating business segments

8.9.4.    Product portfolio

8.9.5.    Business performance

8.9.6.    Key strategic moves and developments

8.10.    QIAGEN N.V.

8.10.1.    Company overview

8.10.2.    Company snapshot

8.10.3.    Operating business segments

8.10.4.    Product portfolio

8.10.5.    Business performance

8.10.6.    Key strategic moves and developments

LIST OF TABLES

TABLE 01.    GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)

TABLE 02.    IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2018–2026 ($MILLION)

TABLE 03.    POLYMERASE CHAIN REACTION MARKET, BY REGION, 2018–2026 ($MILLION)

TABLE 04.    NEXT GENERATION SEQUENCING MARKET, BY REGION, 2018–2026 ($MILLION)

TABLE 05.    IN SITU HYBRIDIZATION MARKET, BY REGION, 2018–2026 ($MILLION)

TABLE 06.    OTHERS MARKET, BY REGION, 2018–2026 ($MILLION)

TABLE 07.    GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026 ($MILLION)

TABLE 08.    COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TYPE, 2018–2026 ($MILLION)

TABLE 09.    COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION, 2018–2026 ($MILLION)

TABLE 10.    COMPANION DIAGNOSTICS FOR NEUROLOGY MARKET, BY REGION, 2018–2026 ($MILLION)

TABLE 11.    COMPANION DIAGNOSTICS FOR OTHERS MARKET, BY REGION, 2018–2026 ($MILLION)

TABLE 12.    COMPANION DIAGNOSTICS MARKET REVENUE, BY REGION, 2018–2026 ($MILLION)

TABLE 13.    NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)

TABLE 14.    U.S. COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 15.    U.S. COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 16.    CANADA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 17.    CANADA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 18.    MEXICO COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 19.    MEXICO COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 20.    NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 21.    NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 22.    EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)

TABLE 23.    GERMONY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 24.    GERMANY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 25.    FRANCE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 26.    FRANCE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 27.    UK COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 28.    UK COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 29.    REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 30.    REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 31.    EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 32.    EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 33.    ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)

TABLE 34.    JAPAN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 35.    JAPAN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 36.    CHINA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 37.    CHINA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 38.    AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 39.    AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 40.    REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 41.    REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 42.    ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 43.    ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 44.    LAMEA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)

TABLE 45.    BRAZIL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 46.    BRAZIL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 47.    SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 48.    SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 49.    REST OF LAMEA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 50.    REST OF LAMEA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 51.    LAMEA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026

TABLE 52.    LAMEA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026

TABLE 53.    ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 54.    ABBOTT LABORATORIES: OPERATING SEGMENTS

TABLE 55.    ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 56.    AGILENT: COMPANY SNAPSHOT

TABLE 57.    AGILENT: OPERATING SEGMENTS

TABLE 58.    AGILENT: PRODUCT PORTFOLIO

TABLE 59.    ARUP LABORATORIES: COMPANY SNAPSHOT

TABLE 60.    ARUP LABORATORIES: SERVICE PORTFOLIO

TABLE 61.    BIOMERIEUX: COMPANY SNAPSHOT

TABLE 62.    BIOMERIEUX: OPERATING SEGMENTS

TABLE 63.    BIOMERIEUX: PRODUCT PORTFOLIO

TABLE 64.    DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 65.    DANAHER CORPORATION: OPERATING SEGMENTS

TABLE 66.    DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 67.    FOUNDATION MEDICINE: COMPANY SNAPSHOT

TABLE 68.    FOUNDATION MEDICINE: SERVICE PORTFOLIO

TABLE 69.    MYRIAD GENETICS, INC: COMPANY SNAPSHOT

TABLE 70.    MYRIAD GENETICS, INC: OPERATING SEGMENTS

TABLE 71.    MYRIAD GENETICS, INC: PRODUCT PORTFOLIO

TABLE 72.    ROCHE: COMPANY SNAPSHOT

TABLE 73.    ROCHE: OPERATING SEGMENTS

TABLE 74.    ROCHE: PRODUCT PORTFOLIO

TABLE 75.    THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT

TABLE 76.    THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS

TABLE 77.    THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO

TABLE 78.    QIAGEN N.V: COMPANY SNAPSHOT

TABLE 79.    QIAGEN N.V: OPERATING SEGMENTS

TABLE 80.    QIAGEN N.V: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.    TOP INVESTMENT POCKETS IN THE GLOBAL COMPANION DIAGNOSTICS MARKET

FIGURE 02.    TOP IMPACTING FACTORS

FIGURE 03.    COMPANION DIAGNOSTICS MARKET SEGMENTATION

FIGURE 04.    MARKET EVOLUTION/ INDUSTRY ROADMAP

FIGURE 05.    IMPACT ANALYSIS

FIGURE 06.    COMPARATIVE ANALYSIS OF IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)

FIGURE 07.    COMPARATIVE ANALYSIS OF POLYMERASE CHAIN REACTION MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)

FIGURE 08.    COMPARATIVE ANALYSIS OF NEXT GENERATION SEQUENCING MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)

FIGURE 09.    COMPARATIVE ANALYSIS OF IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)

FIGURE 10.    COMPARATIVE ANALYSIS OF OTHERS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)

FIGURE 11.    COMPARATIVE ANALYSIS OF COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)

FIGURE 12.    COMPARATIVE ANALYSIS OF COMPANION DIAGNOSTICS FOR NEUROLOGY MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)

FIGURE 13.    COMPARATIVE ANALYSIS OF COMPANION DIAGNOSTICS FOR OTHERS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)

FIGURE 14.    MARKET PLAYER POSITIONING, 2018

FIGURE 15.    TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2019* (%)

FIGURE 16.    TOP WINNING STRATEGIES, BY COMPANY, 2018-2019*

FIGURE 17.    COMPETITIVE DASHBOARD

FIGURE 18.    COMPETITIVE HEATMAP OF KEY PLAYERS

FIGURE 19.    ABBOTT LABORATORIES: NET SALES, 2016–2018 ($MILLION)

FIGURE 20.    ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 21.    ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 22.    AGILENT: NET SALES, 2016–2018 ($MILLION)

FIGURE 23.    AGILENT: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 24.    AGILENT: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 25.    BIOMERIEUX: NET SALES, 2016–2018 ($MILLION)

FIGURE 26.    BIOMERIEUX: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 27.    BIOMERIEUX: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 28.    DANAHER CORPORATION: NET SALES, 2016–2018 ($MILLION)

FIGURE 29.    DANAHER CORPORATION: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 30.    DANAHER CORPORATION: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 31.    MYRIAD GENETICS, INC: NET SALES, 2016–2018 ($MILLION)

FIGURE 32.    MYRIAD GENETICS, INC: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 33.    ROCHE NET SALES, 2016–2018 ($MILLION)

FIGURE 34.    ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 35.    ROCHE: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 36.    THERMO FISHER SCIENTIFIC: NET SALES, 2016–2018 ($MILLION)

FIGURE 37.    THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 38.    THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 39.    QIAGEN N.V: NET SALES, 2016–2018 ($MILLION)

FIGURE 40.    QIAGEN N.V: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 41.    QIAGEN N.V: REVENUE SHARE BY REGION, 2018 (%)